The stock had slumped 9.8 per cent to 5.22 yuan at the close on Friday in Shanghai, capping its biggest decline since May 6. The shares lost 4 per cent to HK$1.70 in Hong Kong.
The two asset-management products were backed by Minxing Pharmaceutical, a drug maker in the northeast province of Fujian, according to the National Business Daily.
In an exchange filing, Central China Securities said it had spotted the risk that the fundraiser may default on payments, and then obtained evidence of falsified documents provided by the fundraiser.